Blair William & Co. IL Has $199.46 Million Holdings in Zoetis Inc. $ZTS

Blair William & Co. IL lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 16.5% during the 3rd quarter, Holdings Channel reports. The firm owned 1,363,155 shares of the company’s stock after selling 268,716 shares during the period. Blair William & Co. IL’s holdings in Zoetis were worth $199,457,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Brighton Jones LLC boosted its stake in Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after acquiring an additional 2,978 shares during the last quarter. Empowered Funds LLC grew its holdings in Zoetis by 6.2% during the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares during the period. Intech Investment Management LLC raised its position in shares of Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after acquiring an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC lifted its stake in shares of Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after purchasing an additional 1,422 shares during the period. Finally, Sigma Planning Corp lifted its stake in shares of Zoetis by 3.1% in the 2nd quarter. Sigma Planning Corp now owns 3,325 shares of the company’s stock valued at $518,000 after purchasing an additional 100 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

Shares of ZTS stock opened at $121.54 on Friday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.00. The firm has a fifty day moving average of $126.06 and a 200-day moving average of $133.20. The firm has a market capitalization of $51.31 billion, a price-to-earnings ratio of 20.19, a price-to-earnings-growth ratio of 1.87 and a beta of 0.95.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is 35.22%.

Analysts Set New Price Targets

Several research firms have recently issued reports on ZTS. KeyCorp began coverage on Zoetis in a research report on Thursday, November 20th. They issued a “sector weight” rating on the stock. William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday. UBS Group set a $136.00 target price on Zoetis in a report on Thursday, January 29th. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. Finally, Bank of America upped their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.